article thumbnail

HeartFlow Initiates DECIDE Registry to Evaluate Utility of HeartFlow AI-Enabled Plaque Analysis for Patients with Suspected Coronary Artery Disease

DAIC

The registry will collect multi-site, real-world information on how the Plaque Analysis product provides enhanced patient insights, empowering physicians and helping to inform their medical management decisions for patients with suspected coronary artery disease (CAD). Rinehart et al. JSCAI 2024 Tzimas et al.

article thumbnail

Results of CERTAIN Study Demonstrate Prominent Effects of Cleerly Products on Changing Clinical Management for Patients Suspected of Coronary Artery Disease

DAIC

It further reported that these results underscore the strong and positive effect of the Cleerly products on clinical utility for patients with suspected coronary artery disease. “We Presented at the American College of Cardiology Annual Scientific Meeting New Orleans LA 2023. 2023 Dec 12:jead339. Barcelona, Spain.

article thumbnail

Long-term outcomes of ischaemia with no obstructive coronary artery disease (INOCA): a systematic review and meta-analysis

Open Heart

Background The prognosis of myocardial ischaemia with no obstructive coronary artery disease (INOCA) and its underlying vasomotor disorders, vasospastic angina (VSA) and microvascular angina (MVA), is not well defined.

article thumbnail

Highlights from the 2023 STS Coronary Conference

Society of Thoracic Surgeons - Congenital

At the 2023 STS Coronary Conference, focus was on the fundamentals and advanced therapies for coronary artery disease, including medical management, arterial conduits, and minimally invasive surgical revascularization.

article thumbnail

Abstract 4143220: Racial Differences in Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among US Veterans with Type 2 Diabetes and Coronary Artery Disease

Circulation

We evaluated patterns of evidence-based prescription of SGLT2i and GLP1RA over time and by race in US Veterans with T2D and coronary artery disease (CAD).Results:Of We evaluated patterns of evidence-based prescription of SGLT2i and GLP1RA over time and by race in US Veterans with T2D and coronary artery disease (CAD).Results:Of

article thumbnail

2023 ESH Hypertension Guideline Update: Bringing Us Closer Together Across the Pond

American College of Cardiology

Hypertension represents a major modifiable risk factor for coronary artery disease (CAD), heart failure (HF), stroke, chronic kidney disease (CKD), and dementia.

article thumbnail

Safe Deferral of Coronary Computed Tomography Angiography for Patients With a Low Pretest Probability of Coronary Artery Disease in 2019 European Society of Cardiology Guidelines

Journal of the American Heart Association

Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023. BackgroundCoronary computed tomography angiography is increasingly used as the first‐line test for suspected coronary artery disease. PTP was calculated according to the 2013 and 2019 ESC guidelines.